Skip to main content

Table 1 Baseline characteristics of patients in matched subgroups by type of ICS use

From: Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

  Permanent users Use at baseline
FP
(n = 825)
Other ICS
(n = 825)
No ICS
(n = 825)
FP
(n = 1334)
Other ICS
(n = 1334)
No ICS
(n = 1334)
Male, n (%) 570 (69.1) 620 (75.2) 624 (75.6) 942 (70.6) 1014 (76.0) 996 (74.7)
Age, years, mean (SD) 65.0 (8.0) 64.9 (8.0) 64.8 (7.8) 64.9 (8.0) 64.9 (7.9) 64.8 (7.8)
Height, cm, mean (SD) 169.81 (9.2) 169.71 (8.6) 170.30 (8.5) 169.52 (9.0) 169.79 (8.4) 169.85 (8.7)
Weight, kg, mean (SD) 77.82 (16.7) 75.09 (15.9) 76.08 (18.1) 76.87 (16.7) 75.41 (16.3) 75.78 (17.9)
Body mass index, kg/m2, mean (SD) 26.89 (5.0) 25.97 (4.6) 26.10 (5.3) 26.65 (5.0) 26.05 (4.8) 26.15 (5.4)
Race, n (%)
 White 808 (97.9) 808 (97.9) 808 (97.9) 1291 (96.8) 1291 (96.8) 1291 (96.8)
 Black 1 (0.1) 1 (0.1) 1 (0.1)
 Asian 17 (2.1) 17 (2.1) 17 (2.1) 42 (3.1) 42 (3.1) 42 (3.1)
Current smoker, n (%) 191 (23.2) 216 (26.2) 298 (36.1) 316 (23.7) 347 (26.0) 473 (35.5)
Non-inhaled steroid use, n (%) 83 (10.1) 78 (9.5) 52 (6.3) 129 (9.7) 114 (8.5) 74 (5.5)
Anticholinergic use, n (%) 422 (51.2) 372 (45.1) 308 (37.3) 692 (51.9) 637 (47.8) 542 (40.6)
GOLD stage, n (%)
 II 395 (47.9) 395 (47.9) 395 (47.9) 621 (46.6) 621 (46.6) 621 (46.6)
 III 371 (45.0) 371 (45.0) 371 (45.0) 608 (45.6) 608 (45.6) 608 (45.6)
 IV 59 (7.2) 59 (7.2) 59 (7.2) 105 (7.9) 105 (7.9) 105 (7.9)
FEV1, L, mean (SD) 1.11 (0.4) 1.12 (0.4) 1.13 (0.4) 1.09 (0.4) 1.10 (0.4) 1.10 (0.4)
FEV1, % predicted, mean (SD) 39.72 (11.4) 39.80 (11.5) 39.78 (11.4) 39.14 (11.5) 39.10 (11.4) 39.17 (11.4)
FVC, L, mean (SD) 2.67 (0.9) 2.70 (0.8) 2.65 (0.8) 2.63 (0.9) 2.67 (0.8) 2.62 (0.8)
FVC, % predicted, mean (SD) 76.20 (18.6) 75.88 (17.4) 73.65 (17.0) 74.99 (18.2) 74.91 (17.5) 73.68 (17.4)
FEV1/FVC, mean (SD) 0.42 (0.1) 0.42 (0.1) 0.43 (0.1) 0.42 (0.1) 0.42 (0.1) 0.43 (0.1)
Post-bronchodilator FEV1, L, mean (SD) 1.34 (0.4) 1.35 (0.4) 1.37 (0.4) 1.32 (0.4) 1.33 (0.4) 1.34 (0.4)
Post-bronchodilator FEV1, % predicted, mean (SD) 48.06 (12.1) 47.90 (12.1) 48.09 (12.0) 47.62 (12.3) 47.30 (12.3) 47.68 (12.4)
  1. Abbreviations: FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, SD standard deviation. Patients within each group were matched by race, age (± 5 years), FEV1% predicted (± 5% predicted), GOLD stage, emphysema diagnosis, and courses of antibiotics during the previous year
\